Federated Hermes Inc. boosted its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) by 14.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,085,139 shares of the company's stock after buying an additional 134,206 shares during the period. Federated Hermes Inc. owned 1.90% of Zentalis Pharmaceuticals worth $30,492,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in the company. Amundi acquired a new position in Zentalis Pharmaceuticals during the second quarter worth approximately $143,000. Legal & General Group Plc grew its stake in shares of Zentalis Pharmaceuticals by 38.1% in the 2nd quarter. Legal & General Group Plc now owns 35,491 shares of the company's stock valued at $998,000 after purchasing an additional 9,791 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Zentalis Pharmaceuticals by 49.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 397,570 shares of the company's stock valued at $11,171,000 after purchasing an additional 132,324 shares during the last quarter. Woodline Partners LP grew its stake in shares of Zentalis Pharmaceuticals by 344.9% in the 2nd quarter. Woodline Partners LP now owns 181,272 shares of the company's stock valued at $5,094,000 after purchasing an additional 140,524 shares during the last quarter. Finally, Thrivent Financial for Lutherans purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $890,000.
Get
Zentalis Pharmaceuticals alerts:
Zentalis Pharmaceuticals Stock Performance
ZNTL opened at $19.38 on Friday. The business's fifty day moving average is $21.96 and its two-hundred day moving average is $24.96. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -4.11 and a beta of 1.80. Zentalis Pharmaceuticals, Inc. has a one year low of $17.33 and a one year high of $85.95.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on the company. Wedbush lowered their target price on Zentalis Pharmaceuticals from $51.00 to $32.00 and set an "outperform" rating on the stock in a research note on Monday, November 14th. SVB Leerink lowered their target price on Zentalis Pharmaceuticals from $42.00 to $27.00 and set an "outperform" rating on the stock in a research note on Thursday, November 10th. Guggenheim lowered their target price on Zentalis Pharmaceuticals from $55.00 to $28.00 and set a "buy" rating on the stock in a research note on Friday, November 11th. Morgan Stanley decreased their price target on Zentalis Pharmaceuticals from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Friday, November 11th. Finally, Wells Fargo & Company decreased their price target on Zentalis Pharmaceuticals from $52.00 to $46.00 in a research note on Monday, November 14th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $46.56.
Insiders Place Their Bets
In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of the business's stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $22.77, for a total transaction of $284,625.00. Following the sale, the president now directly owns 372,011 shares in the company, valued at $8,470,690.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 50,000 shares of company stock worth $1,153,375. 19.90% of the stock is owned by corporate insiders.
About Zentalis Pharmaceuticals
(Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Featured Stories
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating).
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
